Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Cited by (657)

Items 101–200 of 657

1. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
   Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono et al. · 2020 · International Journal of Molecular Sciences
2. Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
   Svegliati-Baroni, Gianluca, Patrício, Bárbara, Lioci, Gessica, Macedo, Maria Paula, Gastaldelli, Amalia · 2020 · International Journal of Molecular Sciences
3. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
   Moein Ala · 2021 · Endocrinology
4. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease
   Sneha Kothari, Hiteshi Dhami-Shah, Samir R. Shah · 2019 · Journal of Clinical and Experimental Hepatology
5. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
   Mengyuan Ge, Judith Molina, Jin‐Ju Kim, Shamroop Kumar Mallela, Anis Ahmad, Javier Varona Santos, Hassan Al‐Ali, Alla V. Mitrofanova, Kumar Sharma, Flavia Fontanesi et al. · 2023 · eLife
6. Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
   JW Kim, Ye‐Jee Lee, Young‐Hye You, Min Kyong Moon, Kun‐Ho Yoon, Yu‐Bae Ahn, Seung‐Hyun Ko · 2018 · Journal of Cellular Biochemistry
7. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice
   Kota Yano, Kanji Yamaguchi, Yuya Seko, Shinya Okishio, Hiroshi Ishiba, Nozomi Tochiki, Aya Takahashi, Seita Kataoka, Keiichiro Okuda, Yu Xin Liu et al. · 2021 · Laboratory Investigation
8. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
   Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, Yip Han Chin, Yi Fen Low, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo · 2021 · Frontiers in Endocrinology
9. SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation
   Liu, Wenhui, You, Danming, Lin, Jiayang, Zou, Huren, Zhang, Lei, Luo, Shenjian, Yuan, Youwen, Wang, Zhiyi, Qi, Jingwen, Wang, Weiwei et al. · 2024 · Cell Metabolism
10. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials
    Coelho, Francisca dos Santos, Borges‐Canha, Marta, von Hafe, Madalena, Neves, João Sérgio, Vale, Catarina, Leite, Ana Rita, Carvalho, Davide, Leite‐Moreira, Adelino · 2021 · Diabetes/Metabolism Research and Reviews
11. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease
    Mengran Shi, Hao Zhang, Wei Wang, Xiao Zhang, Jiawei Liu, Qixian Wang, Yuan Wang, Chunlin Zhang, Xiaoqin Guo, Qiao Qiao et al. · 2023 · Journal of Diabetes and its Complications
12. Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes
    Richeek Pradhan, Hui Yin, Oriana Hoi Yun Yu, Laurent Azoulay · 2022 · Diabetes Care
13. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
    Sungho Bea, Hwa Yeon Ko, Jae Hyun Bae, Young Min Cho, Yoosoo Chang, Seungho Ryu, Christopher D. Byrne, Ju‐Young Shin · 2024 · Gut
14. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
    Matthew M.Y. Lee, Mark Colquhoun Petrie, John J.V. McMurray, Naveed A. Sattar · 2020 · Arteriosclerosis Thrombosis and Vascular Biology
15. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
    Francesco Bellanti, Aurelio Lo Buglio, Michał Dobrakowski, Aleksandra Kasperczyk, Sławomir Kasperczyk, Palok Aich, Shivaram Prasad Singh, Gaetano Serviddio, Gianluigi Vendemiale · 2022 · World Journal of Gastroenterology
16. Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
    Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Haruki Uojima, Keiichiro Yoshikata, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe et al. · 2022 · Hepatology Communications
17. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis
    Bernhard Radlinger, Claudia Ress, Sabrina Folie, Karin Salzmann, Ana Lechuga, Bernhard Weiss, Willi Salvenmoser, Michael Graber, Jakob Hirsch, Johannes Holfeld et al. · 2022 · Diabetologia
18. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations
    Marco A. Arrese, Francisco Barrera M., Nicolás Triantafilo, Juan Pablo Arab · 2019 · Expert Review of Gastroenterology & Hepatology
19. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
    Kyung‐Soo Kim, Byung‐Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong Soo, Cheol‐Young Park · 2019 · Diabetes & Metabolism Journal
20. Novel Therapies for Alport Syndrome
    Efren Chavez, Juanly Rodriguez, Yelena R. Drexler, Alessia Fornoni · 2022 · Frontiers in Medicine
21. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study
    Shigenori Hiruma, Fumika Shigiyama, Naoki Kumashiro · 2023 · Diabetes Obesity and Metabolism
22. Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
    Ka Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, Lok Ka Lam, Lung‐Yi Mak, Yuen Chi Ho, Jing Tong Tan, Esther W. Chan, Wai‐Kay Seto, Man‐Fung Yuen et al. · 2024 · Hepatology
23. NRF-2 and nonalcoholic fatty liver disease
    Arturo Solano-Urrusquieta, José A. Morales‐González, Graciela Castro‐Narro, Eira Cerda Reyes, Perla Denice Flores-Rangel, Raul Fierros-Oceguera · 2020 · Annals of Hepatology
24. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA , a 24‐week, prospective, randomized, placebo‐controlled pilot trial
    Jürgen Harreiter, Ivica Just, Michael Leutner, Magdalena Bastian, Helmut Brath, Christian Schelkshorn, Radka Klepochová, Martin Krššák, Alexandra Kautzky‐Willer · 2021 · Diabetes Obesity and Metabolism
25. Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-κB/Nrf-2/PPAR-γ interplay in mice
    Amir Mohamed Abdelhamid, Ahmed R. El‐Sheakh, Rania Ramadan Abdelaziz, Ghada Mohamed Suddek · 2020 · Life Sciences
26. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
    Dwinata, Michael, Putera, David, Hasan, Irsan, Raharjo, Monica · 2020 · Clinical and Experimental Hepatology
27. Metabolic syndrome and its association with nonalcoholic steatohepatitis
    Bril, Fernando, Sanyal, Arun, Cusi, Kenneth · 2023 · Clinics in Liver Disease
28. The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
    Bertrand Cariou · 2022 · Diabetes Obesity and Metabolism
29. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
    Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Petta · 2018 · Pharmaceuticals
30. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction
    Junzhao Ye, Yanqin Wu, Fuxi Li, Tingfeng Wu, Congxiang Shao, Yansong Lin, Wei Wang, Shi‐Ting Feng, Bihui Zhong · 2019 · Therapeutic Advances in Gastroenterology
31. A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
    Kenneth J. Cusi · 2020 · Liver International
32. Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
    Wayne Huey‐Herng Sheu, Siew Pheng Chan, Bien J. Matawaran, Chaicharn Deerochanawong, Ambrish Mithal, Juliana C.N. Chan, Ketut Suastika, Chin Meng Khoo, Huu Man Nguyen, Linong Ji et al. · 2020 · Diabetes & Metabolism Journal
33. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials
    Cheng Han Ng, Snow Yunni Lin, Yip Han Chin, Ming Hui Lee, Nicholas L. X. Syn, Xin Lei Goh, Jin Hean Koh, Jingxuan Quek, Darren Jun Hao Tan, Shao Feng Mok et al. · 2021 · Endocrine Practice
34. The Gut Microbiome and Ferroptosis in MAFLD
    Jie Ji, Liwei Wu, Jue Wei, Jianye Wu, Chuanyong Guo · 2022 · Journal of Clinical and Translational Hepatology
35. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
    Xianghong Wang, Niujian Wu, Chuanchuan Sun, Donghua Jin, Hongyun Lu · 2023 · Diabetology & Metabolic Syndrome
36. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review
    Bamgboye, Adeboye Olakunle, Oni, Isaac Oluwadamilare, Collier, Andrew · 2021 · European Journal of Clinical Pharmacology
37. SGLT2 Inhibitors in Liver Patients
    Hsiang, John Chen, Wong, Vincent Wai-Sun · 2020 · Clinical Gastroenterology and Hepatology
38. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials
    Zijie Jin, Yan Yuan, Zheng Chen, Shijian Liu, Hongbo Weng · 2023 · Journal of Diabetes and its Complications
39. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
    Chelsea S. Pan, Takara Leah Stanley · 2020 · Frontiers in Endocrinology
40. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease
    Wah‐Kheong Chan, Soek-Siam Tan, Siew-Pheng Chan, Yeong Yeh Lee, Hoi‐Poh Tee, Sanjiv Mahadeva, Khean‐Lee Goh, Anis Safura Ramli, Feisul Idzwan Mustapha, Nik Ritza Kosai et al. · 2022 · Journal of Gastroenterology and Hepatology
41. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
    Stergios A. Pοlyzos, Dimitrios G. Goulis, Όλγα Γιουλεμέ, Georgios S. Germanidis, Antonis Goulas · 2022 · Current Obesity Reports
42. Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
    Yong‐ho Lee, Soo Kyung Lim, Melanie Jane Davies · 2025 · Nature Reviews Endocrinology
43. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
    Surosree Ganguli, Peter Deleeuw, Sanjaya Kumar Satapathy · 2019 · Hepatic Medicine Evidence and Research
44. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
    Shao, Shih-Chieh, Kuo, Liang-Tseng, Chien, Rong-Nan, Hung, Ming-Jui, Lai, Edward Chia-Cheng · 2020 · BMJ Open Diabetes Research & Care
45. Liver-targeting drugs and their effect on blood glucose and hepatic lipids
    Amalia Gastaldelli, Norbert Stefan, Hans‐Ulrich Häring · 2021 · Diabetologia
46. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
    Sahar Hossam El-Hini, Engy A. Wahsh, Ahmed Abdullah Elberry, Nadia Farouk El Ameen, Ahmed Abdel Fadil Saedii, Shereen Mahmoud Refaie, Asmaa A. Elsayed, Hoda Rabea · 2022 · Pharmaceuticals
47. MASLD development: From molecular pathogenesis toward therapeutic strategies
    Zhu Yang, Jiahui Zhao, Kexin Xie, Chengwei Tang, Can Gan, Jinhang Gao · 2025 · Chinese Medical Journal
48. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
    Santo Colosimo, Federico Ravaioli, Maria Letizia Petroni, Lucia Brodosi, Francesca Marchignoli, Francesca Alessandra Barbanti, Anna Simona Sasdelli, Giulio Marchesini, Loris Pironi · 2021 · Liver International
49. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
    Manoj D. Chadha, Ashok Kumar Das, Prasun Deb, Kalyan Kumar Gangopadhyay, Shashank Joshi, Jothydev Kesavadev, RAJIV R. KOVIL, Surender Kumar, Anoop Misra, Viswanathan Mohan · 2022 · Diabetes Therapy
50. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
    Ioana-Cristina Bica, Roxana Adriana Stoica, Teodor Salmen, Andrej Janež, Špela Volčanšek, Djordje S. Popovic, Emir M. Muzurović, Manfredi Rizzo, Anca Pantea Stoian · 2023 · Medicina
51. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
    Luigi Mirarchi, Simona Amodeo, Roberto Citarrella, Anna Licata, Maurizio Soresi, Lydia Giannitrapani · 2022 · International Journal of Molecular Sciences
52. Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
    Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda et al. · 2023 · Biomedicines
53. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
    Xianhua Mao, Xinrong Zhang, Leslie Yeeman Kam, Nicholas Chien, Rongtao Lai, Ka Shing Cheung, Man‐Fung Yuen, Ramsey C Cheung, Wai‐Kay Seto, Mindie H. Nguyen · 2024 · Gut
54. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials
    Tanawan Kongmalai, Varalak Srinonprasert, Thunyarat Anothaisintawee, Pinkawas Kongmalai, Gareth J. McKay, John Attia, Ammarin Thakkinstian · 2023 · Frontiers in Endocrinology
55. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
    Finney, Alexandra C., Das, Sandeep, Kumar, Dhananjay, McKinney, M. Peyton, Cai, Bishuang, Yurdagul, Arif, Rom, Oren · 2023 · Frontiers in Cardiovascular Medicine
56. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
    Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M. et al. · 2020 · Journal of Endocrinological Investigation
57. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
    Yunpeng Gu, Lei Sun, Wei Zhang, Tingting Kong, Run Zhou, Yining He, Chaohua Deng, Luping Yang, Jianing Kong, Yutong Chen et al. · 2023 · Frontiers in Pharmacology
58. Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
    Qiuyu Xu, Jie Zhang, Yan Lu, Ling Ying Wu · 2024 · iScience
59. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I– III clinical trials
    Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon‐Kyu Lee, Ronald C.W., Tien‐Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee et al. · 2018 · Journal of Diabetes Investigation
60. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuyuan Zhang, Xiaobo Liu, Huazhu Zhang, Xuechang Wang · 2022 · Frontiers in Endocrinology
61. Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
    Luca Rinaldi, Chiara Giorgione, Andrea Mormone, Francesca Esposito, Michele Rinaldi, Massimiliano Berretta, Raffaele Marfella, Ciro Pasquale Romano · 2023 · Viruses
62. Liver MR relaxometry at 3T – segmental normal T1 and T2* values in patients without focal or diffuse liver disease and in patients with increased liver fat and elevated liver stiffness
    Verena Carola Obmann, Nando Mertineit, C. Marx, Annalisa Berzigotti, Lukas Ebner, Johannes T. Heverhagen, Andreas Christe, Adrian Thomas Huber · 2019 · Scientific Reports
63. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial
    Hajime Yamakage, Masashi Tanaka, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Noriko Satoh‐Asahara · 2019 · Journal of Diabetes Investigation
64. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study
    Hiroshi Tobita, Tomotaka Yazaki, Masatoshi Kataoka, Satoshi Kotani, Akihiko Oka, Tsuyoshi Mishiro, Naoki Oshima, Kousaku Kawashima, Norihisa Ishimura, Kohji Naora et al. · 2020 · Journal of Clinical Biochemistry and Nutrition
65. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials
    Manjun Deng, Yonghao Wen, Jingxin Yan, Yichen Fan, Zhixin Wang, Ruixia Zhang, Li Ren, Yinggui Ba, Haijiu Wang, Qian Lü et al. · 2023 · BMC Medicine
66. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice
    Kazuno Omori, Akinobu Nakamura, Hideaki Miyoshi, Kiyohiko Takahashi, Naoyuki Kitao, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Ryo Takagi, Kanako C. Hatanaka et al. · 2019 · Metabolism
67. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
    Julia J. Wattacheril · 2019 · Gastroenterology Clinics of North America
68. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
    Gebran W. Khneizer, Syed Rizvi, Samer Gawrieh · 2020 · Advances in experimental medicine and biology
69. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
    SABINE KAHL, Anne Pernille Ofstad, Bernard Zinman, Christoph Wanner, Elke Schueler, Naveed A. Sattar, Silvio E. Inzucchi, Michael Roden · 2022 · Diabetes Obesity and Metabolism
70. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
    Hongle Yan, Chunyi Huang, Xuejun Shen, Jufang Li, Shuyi Zhou, Weiping Li · 2022 · Frontiers in Endocrinology
71. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
    Zhenya Wang, Mao Ye, Xiao‐Jing Zhang, Peng Zhang, Jingjing Cai, Hongliang Li, Zhi‐Gang She · 2022 · Atherosclerosis
72. Targeting peroxisomal fatty acid oxidation improves hepatic steatosis and insulin resistance in obese mice
    Haoya Yao, Yaoqing Wang, Xiao Zhang, Ping Li, Lin Shang, Xiaocui Chen, Jia Zeng · 2022 · Journal of Biological Chemistry
73. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway
    Shaohan Huang, Beibei Wu, Yingzi He, Ruojun Qiu, Tian Yang, Shuo Wang, Yongzhen Lei, Hong Li, Fenping Zheng · 2023 · Hepatology Communications
74. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
    Niki Katsiki, Nikolaos Perakakis, Christos Socrates Mantzoros · 2019 · Metabolism
75. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
    Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Nutrition Metabolism and Cardiovascular Diseases
76. Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities
    Aparamita Pandey, Martín Alcaraz, Pasquale Saggese, Adriana Soto, Estefany Gomez, Shreya Jaldu, Jane Yanagawa, Claudio Scafoglio · 2025 · Cancers
77. Key takeaways from the updated multidisciplinary European MASLD guidelines
    Paul Horn, Frank Tacke · 2025 · eGastroenterology
78. Type 2 diabetes in South Asians
    Anoop Misra, Naveed A. Sattar, Amerta Ghosh, Mahmoud Nassar, Ranil Jayawardena, Ritesh Gupta · 2025 · BMJ
79. Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist
    Carlo Ratti, Mattia Malaguti, Emanuele D’Aniello, Antonio Bellasi, Gianluca Sanna · 2025 · Atherosclerosis
80. Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond
    Angela Sciacqua, Elena Succurro, Giuseppe Armentaro, Sofia Miceli, Daniele Pastori, Giuseppe Rengo, Giorgio Sesti · 2021 · Heart Failure Reviews
81. Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
    Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani, Giovanni Targher, Fernando Bril · 2024 · Metabolites
82. From liver to hormones: The endocrine consequences of cirrhosis
    Juan Eduardo Quiroz Aldave, Elman Rolando Gamarra Osorio, María del Carmen Durand‐Vásquez, Luciana del Pilar Rafael-Robles, Jhean Gabriel Gonzáles Yovera, María Alejandra Quispe-Flores, Luis Alberto Concepción Urteaga, Alejandro Román-Gonzaléz, José Paz‐Ibarra, Marcio José Concepción‐Zavaleta · 2024 · World Journal of Gastroenterology
83. Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
    Ting Li, Ting Fang, Linxin Xu, Xiangyang Liu, Xiaoyu Li, Mei Xue, Xiaochen Yu, Bei Sun, Liming Chen · 2021 · Frontiers in Pharmacology
84. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
    Nikolaos Perakakis, Pavlina Chrysafi, Michael Feigh, Sanne Skovgård Veidal, Christos Socrates Mantzoros · 2021 · International Journal of Molecular Sciences
85. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
    Maria Zachou, Pagona Flevari, Narjes Nasiri Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva N. Kassi, Θεόδωρος Ανδρουτσάκος · 2023 · European Journal of Clinical Pharmacology
86. Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care
    Mario Luca Morieri, Nicola Vitturi, Angelo Avogaro, Giovanni Targher, Gian Paolo Fadini, DARWIN-T2D Network of the Italian Diabetes Society, Agostino Consoli, Gloria Formoso, Giovanni Grossi, Achiropita Pucci et al. · 2021 · Journal of Endocrinological Investigation
87. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
    Saad Saffo, David Edward Kaplan, Nadim Mahmud, Marina Serper, Binu V. John, Joseph S. Ross, Tamar Hamosh Taddei · 2021 · Diabetes Obesity and Metabolism
88. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
    Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Digestive and Liver Disease
89. Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
    Siham Abdelgani, Ahmed Khattab, John M. Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph Anthony DeFronzo, Muhammad A Abdul‐Ghani · 2024 · Diabetes Care
90. Management of diabetes mellitus in patients undergoing liver transplantation
    Valeria Grancini, Veronica Resi, Eva Palmieri, Giuseppe Pugliese, Emanuela Orsi · 2019 · Pharmacological Research
91. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway
    Jun Shirakawa, Kazuki Tajima, Tomoko Okuyama, Mayu Kyohara, Yu Togashi, Dario F. De Jesus, Giorgio Basile, Tatsuya Kin, Andrew M. James Shapiro, Rohit Kulkarni et al. · 2020 · Diabetologia
92. NAFLD in type 2 diabetes mellitus: Still many challenging questions
    Simona Cernea, Itamar Raz · 2020 · Diabetes/Metabolism Research and Reviews
93. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
    Waihong Chung, Kittichai Promrat, Jack R. Wands · 2020 · World Journal of Hepatology
94. Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
    Lucia Brodosi, Salvatore Petta, Maria Letizia Petroni, Giulio Marchesini, Maria Cristina Morelli · 2021 · Transplantation
95. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Yoshitaka Arase, Koichi Shiraishi, Kazuya Anzai, Hirohiko Sato, Erika Teramura, Kota Tsuruya, Shunji Hirose, Ryuzo Deguchi, Masao Toyoda, Tetsuya Mine et al. · 2019 · Clinical Drug Investigation
96. Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
    Xiaodong Zhou, Jeffrey Victor Lazarus, Chayakrit Krittanawong, Giovanni Targher, Christopher D. Byrne, Zobair M. Younossi, Frank Tacke, Qin‐Fen Chen, Christos Socrates Mantzoros, Herbert Tilg et al. · 2026 · The Lancet. Gastroenterology & hepatology
97. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management
    Hersh Shroff, Lisa B. VanWagner · 2020 · Current Hepatology Reports
98. Myopathy Associated With Statins and SGLT2 – A Review of Literature
    Rahul Gupta, Ryan Alcantara, Tarun Popli, Sugandhi Mahajan, Umair Tariq, Raman Dusaj, Aaqib Habib Malik · 2020 · Current Problems in Cardiology
99. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
    Peter S. Wolf, Paul Fellinger, Lorenz Pfleger, Hannes Beiglböck, Patrik Krumpolec, Chiara Barbieri, Amalia Gastaldelli, Jürgen Harreiter, Matthäus Metz, Thomas Scherer et al. · 2020 · Diabetes Care
100. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
     Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama et al. · 2021 · Therapeutic Advances in Endocrinology and Metabolism